(Information sent by the signatory company)
The exciting combination of product solutions will create a leading neurodiagnostic and neuromonitoring portfolio supported by an organization of knowledgeable and passionate experts.
MIDDLETON, Wis., December 2, 2022 /PRNewswire/ — Natus Medical Incorporated (the “Company” or “Natus”), a leading provider of medical device solutions focused on the detection, diagnosis and treatment of central nervous system and sensory disorders, has entered into a definitive agreement to acquire Micromed Holding SAS ( “Micromed Group” or “Micromed”), a global provider of neurophysiology solutions. The transaction is expected to close in early 2023, subject to receipt of regulatory clearances.
The Micromed acquisition will be Natus’ first transaction since it was acquired by ArchiMed Group (“ARCHIMED”) in July of this year. “We are delighted to make this first growth-oriented investment as an ARCHIMED portfolio company,” said Thomas J. Sullivan, CEO of Natus. “The breadth and depth of Natus and Micromed’s clinical experience will enable us to bring exciting innovations to our neuroscience customers and their patients around the world.”
Together, Natus and Micromed will provide customers with a best-in-class portfolio of neurodiagnostic and neuromonitoring solutions. A legacy of Born of More than 85 years of leadership in neurodiagnostics including brands such as NeuroWorks®/SleepWorks™, Natus Quantum®, Grass ®, Nicolet®, Xltek®, Embla®, Dantec™ TECA® and others will be combined with Micromed’s full line of solutions , including BRAIN QUICK®/MYOQUICK®, NEUROWERK®, SleepRT® and MOBERG. The products will also enable a strong platform for new product development in electroencephalography (EEG), polysomnography (PSG), electromyography (EMG) and intensive care unit (ICU) monitoring through the integration of the best aspects of both portfolios. of products, including compatibility with previous versions.
“The joining forces of the Natus and Micromed teams, with their collective knowledge and passion for neurodiagnostics and neurocritical care, will result in both a more comprehensive product offering and an unrivaled global service and support structure.” for the benefit of our customers,” said Austin Nollpresident of Natus and leader of Born Neuro. Noll added that “the leadership of our new team of Born Neuro will work closely with Micromed management to build on Micromed’s momentum in the European epilepsy market and Moberg’s emerging presence in ICUs.”
About the birth – www.natus.com -Natus offers innovative and reliable solutions to examine, diagnose and treat disorders that affect the brain, neural pathways and the eight sensory nervous systems, in order to advance the standard of care and improve the outcomes and quality of life of the patients. The company offers advanced hardware, software, algorithms, and consumables that deliver stimuli, acquire and monitor physiological signals, and capture the body’s response. With sales in more than 100 countries, Natus is a leader in neurodiagnostics, pediatric retinal imaging and infant hearing screening, as well as a leading company in hearing evaluation, hearing aid fitting, balance and intracranial pressure monitoring. The Natus product portfolio represents a heritage of innovation and leadership. Natus brands have been setting the standard in patient care for more than 85 years. Our products are trusted by medical professionals at university medical centers, hospitals, private practices, clinics, and research laboratories around the world. Natus supports the changing needs of our customers with clinical expertise, continuing education, and exceptional technical service.
About Micromed – Founded in 1982, Micromed is a medical device company that provides neurophysiology solutions to more than 78 countries around the world. In partnership with hospitals, sleep laboratories, and research centers worldwide, Micromed manufactures and markets high-quality, cost-effective, and clinically relevant neurodiagnostic hardware and software to neurologists, clinicians, and researchers for use in adult and pediatric patients. Micromed’s product portfolio ranges from routine, ambulatory, and video EEG to electrocorticography (ECoG), stereoelectroencephalography (SEEG), PSG, evoked potentials (EP), EMG, and ICU multimodality monitoring solutions for clinic and research.
About ARCHIMED – www.archimed.group – With offices in the US and Europe, ARCHIMED is a leading investment firm focused exclusively on the healthcare industries. Its combination of operational, medical, scientific, and financial expertise enables ARCHIMED to act as a strategic and financial partner to North American and European healthcare companies. Priority areas of interest are biopharmaceutical products and services, life science tools, medical devices and technologies, in vitro diagnostics, health information technology, and consumer health. ARCHIMED helps its partners to internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ARCHIMED’s management team has directly managed and invested in more than eighty large and small healthcare companies around the world, representing more than €50 billion in combined value. ARCHIMED manages 6,000 million euros in its different funds. Since its creation, ARCHIMED has been a committed impact investor, both directly and through its EURÊKA Foundation.
Contacts:
Natus Medical IncorporatedInvestorRelations@Natus.com
ARCHIMED France: Stephanie du Ché, stephanie.duche@archimed.group+33 (0)6 16 36 11 08;International: David Lanchner, dlanchner@lanchner.com+33 (0)6 33 43 50 76
View original content: https://www.prnewswire.com/news-releases/natus-medical-incorporated-adquiere-micromed-holding-sas-301692832.html